Login to Your Account

Aventis Drops Genasense Deal On Phase III CLL Data

By Karen Pihl-Carey

Wednesday, November 10, 2004
Losing half of its value, Genta Inc.'s stock slid south on Tuesday following news that Genasense did not meet key secondary endpoints and had safety issues in a Phase III trial, causing Aventis to drop out as a marketing partner. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription